# Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy

> **NCT02112838** · PHASE2 · COMPLETED · sponsor: **Rigel Pharmaceuticals** · enrollment: 76 (actual)

## Conditions studied

- IGA Nephropathy

## Interventions

- **DRUG:** Fostamatinib 150 mg
- **DRUG:** Fostamatinib 100 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02112838
- **Lead sponsor:** Rigel Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10
- **Primary completion:** 2018-03-23
- **Final completion:** 2018-11-12
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2019-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02112838

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02112838, "Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02112838. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*